Delve Bio

Based in the United States, Delve Bio is a startup. Its most recent tracked round is Series A. Brouky classifies it under Healthcare & Life Sciences. Brouky records 1 investor associated with the company.

Delve Bio offers a metagenomic next-generation sequencing diagnostic test, Delve Detect, that rapidly identifies a wide range of pathogens including bacteria, viruses, fungi, and parasites in cerebrospinal fluid to aid in the diagnosis of central nervous system infections such as meningitis and encephalitis.